Erectile dysfunction decisions — 2024

The Veteran's need for aid and attendance is due to his service-connected peripheral neuropathy of the right lower extremity associated with diabetes type II with erectile dysfunction.

The Veteran's appeal of the issues related to a muscle injury, left shoulder tendonitis, and lumbosacral strain is dismissed. Service connection for squamous cell carcinoma of the tongue, cancer of the lymph nodes secondary to squamous cell carcinoma of the tongue, hypothyroidism secondary to squamous cell carcinoma of the tongue, gastroesophageal reflux disease (GERD) secondary to squamous cell carcinoma of the tongue, and a scar of the right neck secondary to squamous cell carcinoma of the tongue is granted. The Veteran's erectile dysfunction secondary to squamous cell carcinoma of the tongue is also granted.

The Board denied the Veteran's claim for an earlier effective date for service connection of erectile dysfunction, finding that the earliest date entitlement arose was February 23, 2022.

The Board has remanded the claims for service connection due to a duty to assist error, and will consider each issue individually.

The Veteran's claims for earlier effective dates and increased ratings were denied. The Veteran was granted a 10% rating for unspecified anxiety disorder as of July 1, 2022, but the appeal is pending for ED and depression.

The Veteran's claim for an earlier effective date for the rating increase to 100 percent for PTSD is denied due to a lack of evidence demonstrating total occupational and social impairment during the year prior to September 24, 2020.,The claims for service connection for hypertension, OSA, erectile dysfunction, and tinnitus are remanded as insufficient development was performed.

The Board has denied the Veteran's claims for service connection for right shoulder disability and erectile dysfunction, finding that there is no evidence to support a nexus between these conditions and his active service or service-connected back disability. The Board also found insufficient medical evidence to determine if the Veteran's erectile dysfunction was due to his service-connected psychiatric disability.

The Board denied the Veteran's claims for service connection for obstructive sleep apnea and erectile dysfunction as secondary to his service-connected major depressive disorder.,The Board also denied the Veteran's claim for service connection for fatigue due to obstructive sleep apnea, finding that it is less likely than not related to active service.

The Board has decided to remand the case due to an inadequate opinion regarding whether the Veteran's erectile dysfunction is secondary to his service-connected major depressive disorder.

The Veteran's service-connected disabilities, including Parkinson's disease and tremors, prevent him from securing or following a substantially gainful occupation. The Board has granted the TDIU.

The Board has remanded the claim of service connection for erectile dysfunction, as it is related to service-connected PTSD. The Veteran was not examined due to his refusal and the examiner's opinion is inadequate.

The Board has granted service connection for erectile dysfunction, finding that it is secondary to the Veteran's service-connected prostate cancer. The decision also acknowledges that the Veteran was not previously service connected for prostate cancer at the time of the initial rating decision.

The Veteran's erectile dysfunction is granted as secondary to his unspecified depressive disorder, and he is also granted special monthly compensation based on loss of use of a creative organ.

The Veteran's right ankle tendonitis is rated at 10 percent, but the Board finds that a higher rating is not warranted.,Service connection for erectile dysfunction as secondary to service-connected bilateral plantar fasciitis was denied. The Veteran's tinnitus, however, has been granted service connection.

The Board has decided to remand the Veteran's claims for service connection due to pre-decisional duty to assist errors. The claims will be returned for further development and readjudication.

The Veteran's claim for service connection for erectile dysfunction is granted as the evidence supports that his current condition had its onset during active service and is related to an in-service event.,The Veteran's claim for service connection for hypertension is denied as there is no persuasive evidence linking his current diagnosis to his active service.

The Board has remanded the claims of entitlement to service connection for an acquired psychiatric disorder and for an eye disability due to potential errors in obtaining relevant medical records.,Specifically, the Veteran's VA treatment records do not indicate that audiometric testing was performed, which is necessary to determine if a hearing loss disability exists. Additionally, no opinion regarding the relationship between any current eye disability and service participation in a toxic exposure risk activity (TERA) has been provided.

The Veteran's claims for earlier effective dates for erectile dysfunction and headaches were denied as the earliest possible date under the law is October 28, 2022.,The Veteran's claims for compensable ratings for erectile dysfunction and headaches were also denied due to lack of supporting evidence.

The Veteran's PTSD is rated at 70 percent, and the Board finds it does not warrant a higher rating.,The Veteran's prostate cancer residuals are rated at 40 percent, and the Board finds it does not warrant a higher rating.,The Veteran's erectile dysfunction does not meet the criteria for a compensable disability rating.,The claims of service connection for a low back disability and an increased disability rating for right knee strain have been remanded by the Board.,No specific effective date provided as this is an initial decision.

The Veteran's claims for service connection related to DM, diabetic peripheral neuropathy, diabetic retinopathy, hypertension, and CAD have been granted under the PACT Act. The Veteran was exposed to herbicide agents in Guam.,Service connection has also been established for prostate cancer and Parkinson's Disease.